Advanced

Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer

De Marchi, Tommaso LU ; Foekens, John A.; Umar, Arzu and Martens, John W. M. (2016) In Drug Discovery Today 21(7). p.8-1181
Abstract

Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.

Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
in
Drug Discovery Today
volume
21
issue
7
pages
8 pages
publisher
Elsevier
external identifiers
  • scopus:84969921763
ISSN
1878-5832
DOI
10.1016/j.drudis.2016.05.012
language
English
LU publication?
no
id
d7c8b01e-0eb3-49ac-a1e2-16ee7272dbc9
date added to LUP
2017-06-27 14:33:48
date last changed
2017-11-12 04:33:07
@article{d7c8b01e-0eb3-49ac-a1e2-16ee7272dbc9,
  abstract     = {<p>Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.</p>},
  author       = {De Marchi, Tommaso and Foekens, John A. and Umar, Arzu and Martens, John W. M.},
  issn         = {1878-5832},
  language     = {eng},
  number       = {7},
  pages        = {8--1181},
  publisher    = {Elsevier},
  series       = {Drug Discovery Today},
  title        = {Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer},
  url          = {http://dx.doi.org/10.1016/j.drudis.2016.05.012},
  volume       = {21},
  year         = {2016},
}